MedPath
TGA Approval

GARDASIL 9 Human Papillomavirus 9-valent Vaccine, Recombinant, 30, 40, 60, 40, 20, 20, 20, 20, 20 micrograms/0.5mL, suspension for injection, syringe (224092)

224092

GARDASIL 9 Human Papillomavirus 9-valent Vaccine, Recombinant, 30, 40, 60, 40, 20, 20, 20, 20, 20 micrograms/0.5mL, suspension for injection, syringe

Merck Sharp & Dohme (Australia) Pty Ltd

June 29, 2015

Medicine

Medicine

Active

Registered

Product Information

Consumer Medicine Information

https://medical-cdn.nocode.com/drug_tga/9775bb712e66da43bb00c293dbc08622.pdf

Product Information

https://medical-cdn.nocode.com/drug_tga/ccc4c0ae57ff694a3c6acf2260d71a51.pdf

Active Ingredients

HPV Type 11 L1 Protein

HPV Type 16 L1 Protein

HPV Type 18 L1 Protein

HPV Type 31 L1 Protein

HPV Type 33 L1 Protein

HPV Type 45 L1 Protein

HPV Type 52 L1 Protein

HPV Type 58 L1 Protein

HPV Type 6 L1 Protein

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

GARDASIL 9 Human Papillomavirus 9-valent Vaccine, Recombinant, 30, 40, 60, 40, 20, 20, 20, 20, 20 micrograms/0.5mL, suspension for injection, syringe (224092) - TGA 批准文号 | MedPath